Comparative analysis of humoral immune response upon the three first vaccines applied in Argentina: IgG production and neutralizing capacity against SARS-CoV-2.

Autor:	Giai C; Instituto de Histología y Embriología de Mendoza (IHEM)-UNCuyo-CONICET-Ciudad Universitaria, Mendoza, Argentina., Salassa BN; Instituto de Histología y Embriología de Mendoza (IHEM)-UNCuyo-CONICET-Ciudad Universitaria, Mendoza, Argentina., Zarelli VE; Instituto de Histología y Embriología de Mendoza (IHEM)-UNCuyo-CONICET-Ciudad Universitaria, Mendoza, Argentina., Bello OD; Instituto de Histología y Embriología de Mendoza (IHEM)-UNCuyo-CONICET-Ciudad Universitaria, Mendoza, Argentina., Vanrell MC; Instituto de Histología y Embriología de Mendoza (IHEM)-UNCuyo-CONICET-Ciudad Universitaria, Mendoza, Argentina., Ojeda DS; Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina., Gamarnik A; Fundación Instituto Leloir-CONICET, Buenos Aires, Argentina., Colombo MI; Instituto de Histología y Embriología de Mendoza (IHEM)-UNCuyo-CONICET-Ciudad Universitaria, Mendoza, Argentina.
Jazyk:	angličtina
Zdroj:	Heliyon [Heliyon] 2023 May; Vol. 9 (5), pp. e15211. Date of Electronic Publication: 2023 Apr 19.
DOI:	10.1016/j.heliyon.2023.e15211
Abstrakt:	The population that has not received a SARS-CoV-2 vaccine is at high risk for infection whereas vaccination prevents COVID-19 severe disease, hospitalization, and death. In Argentina, to date, more than 50 million doses of vaccines against SARS-CoV-2 have been administered. The three main vaccines applied are Sputnik V, Oxford-AstraZeneca, and Sinopharm. In this study, we have compared the antibody response of voluntary individuals at day 0 (first dose vaccination day) and at 21-25 days post first and second dose. Our results indicate that at 21-25 days after the administration of the first doses of Sputnik V the large majority of the people vaccinated 80% (n = 15) presented high humoral responses as determined by the measurement of IgG against the Spike protein and the Receptor Binding Domain (RBD). In the case of those vaccinated with AstraZeneca, the percentage was 80% (n = 15) whereas this value was reduced to only 25% (n = 16) in persons that received Sinopharm. However, after the second doses, most of the recipients had significant levels of antibodies. The virus neutralizing capacity of the antibodies generated was evaluated using a pseudotyped VSV-SARS-CoV2 Spike expressing eGFP and the data was analyzed by fluorescence microscopy and flow cytometry. The results indicate that a good correlation exists between the levels of IgG and the neutralizing capacity of the antibodies against the recombinant virus. Our results stand out the importance of applying the second dose of Sinopharm. Thus, the present report provides data that will contribute to decisions making about the vaccine implementation plans of action for, not only our region but our country to support the fight against the COVID-19 global pandemic. Competing Interests: The authors declare no competing interests. (© 2023 Published by Elsevier Ltd.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu